Journal of Cancer Prevention

eISSN 2288-3657
pISSN 2288-3649

Results of the bivariable and multivariable cox regression analysis of colorectal cancer patients in TASH, Addis Ababa, Ethiopia

Variable Category Bivariable CHR (95% CI) Multivariable AHR (95% CI)
Sex Female 1 1
Male 1.4 (1.047-1.86)* 0.89 (0.64-1.24)
Age of patient (yr) < 40 1 1
40-49 1.1 (0.71-1.73) 0.97 (0.60-1.55)
50-59 0.93 (0.62-1.39) 0.86 (0.50-1.34)
60-69 2.2 (1.46-3.28)*** 1.5 (0.98-2.40)
≥ 70 2.9 (1.89-4.66)*** 1.7 (1.02-2.90)*
Residence Rural 1 1
Urban 1.3 (0.97-1.77) 1.3 (0.93-1.80)
Marital status Single 1 1
Married 1.4 (0.96-2.105) 2.4 (1.50-3.80)***
Widowed 2.3 (1.31-3.9)** 2.4 (1.20-4.60)**
Divorced 2.7 (1.62-4.4)*** 2.0 (1.1-3.7)*
Smoking status No 1 1
Yes 2.4 (1.80-3.19)*** 1.6 (1.10-2.30)*
Alcohol consumption No 1 1
Yes 2.1 (1.59- 2.76)*** 1.5 (1.07-2.20)*
Comorbidity No 1 1
Yes 2.7 (2.10-5.66)*** 1.8 (1.30-2.50)***
Stage at diagnosisa Stage I 1 1
Stage II 4.8 (1.7-13.9)** 3.8 (1.3-11.1)*
Stage III 8.9 (3.2-24.7)*** 8.0 (2.8-23.3)***
Stage IV 18.1 (6.6-50.1)*** 17.6 (6.1-50.7)***
Grades of cancer Differentiated 1 1
Moderately differentiated 1.6 (1.14-2.4)** 1.4 (0.94-2.03)
Undifferentiated 2.8 (2.04-3.89)*** 1.7 (1.17-2.4)**
Histology type Adenocarcinoma 1 1
Mucinous carcinoma 1.4 (0.97-2.02) 1.2 (0.80-1.75)
Signet-ring-cell carcinoma 1.8 (1.1-2.9)* 1.3 (0.71-2.19)
Treatment modality Radiation alone 1 1
Surgical treatment alone 0.89 (0.37-2.07) 0.85 (0.35-2.1)
Chemotherapy alone 1.8 (0.92-3.5) 0.82 (0.40-1.7)
Surgery plus chemotherapy 1.2 (0.61-2.2) 0.67 (0.34-1.3)
Radiation as neo-adjuvant to surgery 1.2 (0.58-2.6) 0.82 (0.37-1.8)
Radiation + surgery + chemotherapy 1.5 (0.80-2.89) 0.69 (0.34-1.4)
Didn’t receive treatment 0.83 (0.10-6.47) 0.6 (0.07-5.4)

The total number of 621 subjects were selected from patients registered between January 1, 2013 and December 30, 2017 with follow-up until December 30, 2018. TASH, Tikur Anbessa Specialized Hospital; CHR, crude hazard ratio; AHR, adjusted hazard ratio. aAccording to American Joint Committee of Cancer. *ignificant (P < 0.05), **significant (P < 0.01), ***significant (P < 0.001).

Journal of Cancer Prevention 2020;25:38~47 https://doi.org/10.15430/JCP.2020.25.1.38
© J Cancer Prev
Copyright © Korean Society of Cancer Prevention. / Powered by INFOrang Co., Ltd